Ocugen Licenses OCU400 Gene Therapy to Kwangdong for Korean Market

Ocugen partnered with Kwangdong to bring OCU400, a potential one-time gene therapy for RP blindness, to Korea. This could help 7,000 patients and brings Ocugen up to $7.5M upfront + royalties.